At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 333 enrolled
Drug / intervention
Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate +2 morebiological
Likely dose
Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate 0.5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Exploratory Evaluation of a Two-dose Schedule Versus a One-dose Schedule of Menactra® (Meningococcal [Groups A, C, Y and W 135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) in Children in the US
In Brief
A Phase 2 clinical trial evaluating Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate for Meningitis and 2 related conditions. Completed, enrolled 333 participants across 15 sites.
Detailed Summary
To explore the potential benefit of the administration of Menactra vaccine as a two-dose regimen to children. Primary Objective: To assess, by age group, the immune response to Menactra vaccine after each vaccine injection.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMeningitis, Meningococcal Infection, Neisseria Meningitidis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2008
First PostedJun 2008
Primary CompletionMay 2009
Study CompletionOct 2009
TodayJul 2026
First PostedJun 19, 2008
Enrollment StartJun 1, 2008
Primary CompletionMay 1, 2009
Study CompletionOct 1, 2009
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 18.0 years ago
Interventions
Menactra®: Meningococcal Polysaccharide Diphtheria Conjugatebiological
0.5 mL, 2 doses Intramuscular
Menactra®: Meningococcal Polysaccharide Diphtheria Conjugatebiological
0.5 mL, 2 doses Intramuscular
Menactra®: Meningococcal Polysaccharide Diphtheria Conjugatebiological
0.5 mL, 1 dose Intramuscular